Cantor Fitzgerald Cuts Price Target On This Cannabis MSO, But Touts Its Operations As 'One Of Best-In-Class'
Cantor Fitzgerald Cuts Price Target On This Cannabis MSO, But Touts Its Operations As 'One Of Best-In-Class'
Cresco Labs Inc. (CSE:CL) (OTCQX:CRLBF) reported its financial results on Wednesday for the second quarter of fiscal 2022, revealing a 4% year-over-year increase in revenue to $218 million.
Cresco Labs Inc.（CSE: CL）（OTCQX: CRLBF）週三公佈了2022財年第二季度的財務業績，顯示收入同比增長4％，達到2.18億美元。
The transaction with Columbia Care Inc. (OTCQX:CCHWF) (NEO:CCHW) (CSE:CCHW) (FSE: 3LP) is proceeding as expected," Charles Bachtell, the company's CEO and co-founder, said in a press release adding that "the divestiture and regulatory processes are on track and we continue to anticipate a closing around year-end."
與哥倫比亞醫療公司（OTCQX: CCHWF）（NEO: CCHW）（CSE: CCHW）（FSE: CCHW）（FSE：3LP）的交易正在按預期進行。” 該公司首席執行官兼聯合創始人查爾斯·巴赫特爾在一份新聞稿中補充說：“剝離和監管程序已步入正軌，我們仍然預計將在年底左右完成。”
Cantor Fitzgerald's analyst Pablo Zuanic addressed the company's earnings in his recent note, highlighting that that sequential revenue growth of 2% was below his estimate.
坎託·菲茨傑拉德的分析師巴勃羅·祖安尼奇在最近的報告中談到了該公司的收益，強調2％的連續收入增長低於他的預期。
The Analyst
分析師
Zuanic retained Overweight ratings on both Cresco's and Columbia Care's stocks but lowered his 12-month price target for Cresco to $15 from $19 due to the reduced estimates, and disclosed a price target for Columbia of $8.37, up from $5.10.
Zuanic維持了對Cresco和Columbia Care股票的增持評級，但由於估計值下調，將Cresco的12個月目標股價從19美元下調至15美元，並披露哥倫比亞的目標股價爲8.37美元，高於5.10美元。
The Thesis
論文
The analyst said the slight quarter-over-quarter revenue increase is "understandable" if taking into account Cresco's footprint and the fact that none of those states will go recreational in the second half of 2022.
這位分析師表示，如果考慮到Cresco的足跡以及這些州都不會在2022年下半年轉向娛樂業這一事實，收入同比略有增長是 “可以理解的”。
However, he added that the "stock has optionality from several states in the east potentially going rec in the coming years."
但是，他補充說：“該股具有來自東部幾個州的期權，未來幾年可能會出現回升。”
Commenting on the deal to acquire its rival Columbia Care for $2.1 billion, which was announced in March, Zuanic said Cresco is now focused on closing the transaction, adding that "divestitures from the merger are seen raising gross proceeds north of $300 million."
Zuanic在評論3月份宣佈的以21億美元收購競爭對手哥倫比亞醫療的交易時說，Cresco現在正專注於完成交易，並補充說：“合併後的資產剝離預計將使總收益提高到3億美元以上。”
The company "runs one of the best-in-class operations in the MSO space," the analyst said, referring to its revenue, store count as well as wholesale presence, and presence in key states.
這位分析師表示，該公司 “在MSO領域經營着一流的業務之一”，指的是其收入、門店數量和批發業務以及在主要州的業務。
CRLBF Price Action
CRLBF 價格走勢
Cresco's shares traded $3.2% lower at $3.63 per share at the market close on Wednesday.
週三收盤時，Cresco的股價下跌3.2％，至每股3.63美元。
CCHWF Price Action
CCHWF 價格走勢
Columbia Care's shares traded 3.19% lower at $1.82 per share at the market close on Wednesday.
週三收盤時，哥倫比亞醫療股價下跌3.19％，至每股1.82美元。
Benzinga Cannabis Capital Conference
本辛加大麻資本會議
Come and meet Pablo Zuanic, Charles Bachtell, and other extraordinary cannabis visionaries at the Benzinga Cannabis Capital Conference, which returns this fall in Chicago and stay at the historic Palmer House Hotel. Don't miss out on a chance to hear about future market forecasts and worldly advice on investing and finance from those embedded in the cannabis industry.
快來本辛加大麻資本會議上與巴勃羅·祖安尼奇、查爾斯·巴赫特爾和其他非凡的大麻遠見卓識者見面，該會議將於今年秋天在芝加哥回歸，入住歷史悠久的帕爾默故居酒店。千萬不要錯過聽取大麻行業內人士對未來市場預測以及有關投資和融資的世俗建議的機會。
Book your tickets HERE, and your room HERE.
在這裏預訂門票，在這裏預訂房間。
Photo: Courtesy of gerald by Pixabay
照片：由 Pixabay 提供 gerald